Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Food Allergy Clinical Trial

Official title:

Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03679676
• Other study ID #: IRB-47935
• Secondary ID: 5U19AI104209-07
• Status: Recruiting
• Phase: Phase 2
• Start date: February 5, 2020
• Est. completion date: September 2025

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: SNP Center Inquiry
• Phone: 650-521-7237
• Email: snpcenterallergy_inquiry[@]stanford.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

Description:

This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be peanut. The total population will be 110 participants, ages 4 to 55 years that present with a history of multiple food allergies of 2 or 3 different foods including peanut, food-allergen (FA)-specific IgE levels, and positive skin prick test (SPT). Enrolled participants must react positively during DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins of 2 or 3 allergens in which one must be a peanut. There will be three study cohorts, all will be double blinded: Cohort A (50 participants) will be treated with omalizumab for 8 weeks followed by 24 weeks of treatment with placebo. Cohort B (50 participants) will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab. Cohort C (10 participants) will be treated with placebo for 8 weeks followed by 24 weeks treatment with dupilumab. All cohorts will receive multifood allergen oral immunotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: September 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age 4 through 55 years (inclusive).
• Clinical history of peanut allergy and 1 or 2 additional foods from the following foods: milk, almond, shellfish, fish, cashew, hazelnut, egg, walnut, sesame seeds, soy, and wheat. Allergy to milk and egg is defined as unable to tolerate both cooked and uncooked forms.
• Positive allergy test determined by:
• ImmunoCAP serum IgE level >4 kUA/L for each allergen within the past 12 months OR
• Skin prick test (SPT) =6 mm wheal diameter to each allergen.
• A clinical reaction during a DBPCFC to small doses of food defined as a cumulative dose of =/<444 mg food protein.
• No clinical reaction observed during the placebo (oat) challenge.
• Subject and/or parent guardian must be able to understand and provide informed consent.
• Written informed consent from adult participants.
• Written informed consent from parent/guardian for minor participants.
• Written assent from minor participants as appropriate (e.g., at and above the age of 7 years).
• Use of effective birth control by female participants of childbearing potential.

Exclusion Criteria:

• History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension.
• Individuals less than 15 kg in weight at start of the study
• History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation.
• History of chronic disease (other than asthma, atopic dermatitis or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen.
• History of eosinophilic esophagitis (EoE), another eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia (e.g., difficulty swallowing, food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology.
• Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
• Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if uncontrolled or difficult to control.
• Uncontrolled asthma as evidenced by:
• FEV1 < 80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) < 75% of predicted, with or without controller medications (only for age 6 or greater and able to do spirometry reliably. If unable to do spirometry, PEF of >80% is acceptable) or;
• One overnight admission to a hospital in the past year for asthma or;
• Emergency room (ER) visit for asthma within six months prior to screening.
• Inability to tolerate biological (antibody) therapies.
• Use of immunomodulator therapy (not including corticosteroids).
• Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers.
• Current participation or within the last 4 months in any other interventional study.
• Pregnancy or lactation.
• Allergy to oat (placebo in DBPCFC).
• Use of investigational drugs within 16 weeks of participation.
• In build up phase of immunotherapy for aeroallergens or venom.

Related Conditions & MeSH terms

• Food Allergy
• Food Hypersensitivity
• Hypersensitivity
• Hypersensitivity, Food
• Peanut Allergy
• Peanut Hypersensitivity

Intervention

Drug:
• Omalizumab
Omalizumab is injected every 2 to 4 weeks
• Dupilumab
Dupilumab is injected every 2 weeks combination, or placebo.

Other:
• Placebo
Placebo is injected every 2 to 4 weeks

Locations

Country	Name	City	State
United States	University of California Los Angeles (UCLA)	Los Angeles	California
United States	Sean N. Parker Center for Allergy & Asthma Research at Stanford University	Palo Alto	California
United States	University of California San Diego (UCSD)	San Diego	California

Sponsors (4)

Lead Sponsor	Collaborator
Stanford University	Food Allergy Research & Education, Harvard School of Public Health (HSPH), National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The success rates of passing a peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC)	Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.	44 weeks
Primary	The success rates of passing a DBPCFC to peanut and at least one other FA	Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.	44 weeks
Primary	The success rates of passing a DBPCFC to peanut and two other FAs	Success is defined as passing a cumulative dose of >=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B.	44 weeks
Secondary	Proportion of participants who successfully pass DBPCFCs to a cumulative dose of >=1,043 mg protein to 1, 2, or 3 FAs when applicable at week 44		44 weeks
Secondary	Proportion of participants who successfully pass DBPCFCs to a cumulative dose of =2,043 mg to 1, 2, or 3 FAs when applicable at week 32		32 weeks
Secondary	Proportion of participants who pass DBPCFCs for each FA at a cumulative dose of =1,043 mg, =2,043 mg, or =4,043 mg at week 32 and/or week 44.		week 32 and/or 44
Secondary	Proportion of participants who have a 10-fold change in the cumulative tolerance dose for each FA at weeks 32 and/or week 44, compared to baseline		Baseline and week 32 and/or 44

External Links

•   Related Info